|Mr. Dietrich John Pauls MBA||Pres, CEO & Director||687.58k||N/A||1971|
|Mr. Scott B. Kellen C.A.||CFO & Company Sec.||370.16k||N/A||1965|
|Dr. Harry W. Alcorn Jr., Pharm.D.||Sr. VP of Clinical Operations||389.93k||N/A||1956|
|Dr. Edward G. Calamai Ph.D.||Consulting Head of Manufacturing||N/A||N/A||N/A|
|Dr. Kirsten L. Gruis M.D., M.S.||Chief Medical Officer||N/A||N/A||N/A|
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.